Advinus in talks to outlicense diabetes drug molecule

NEW DELHI: Tata group company Advinus Therapeutics has completed initial trials of a new molecule to treat type II diabetes and is in talks with a few global drugmakers to outlicense the molecule, a top company executive said.

The privately held company has sought the Indian drug regulator’s nod to go ahead with the phase II (a) trial of its molecules in multiple dosages, which essentially means trying it out on a larger number of patients and healthy individuals.

If the molecule is commercialised it could have a significantly higher efficacy and safety profile over the existing drugs available in market to treat the diabetes in the market, Rashmi Barbhaiya, CEO and managing director, Advinus Therapeutics said.